Vascular Biology |
From the Department of Physiology and Cellular Biophysics (J.H., A.O., S.C.S.), Columbia University, and the Division of Hematology/Oncology (M.F.), Department of Medicine, Weill Medical College of Cornell University, New York, NY; and the Department of Molecular Biology and Medicine (T.K.), Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Correspondence to Jens Husemann, MD, Department of Physiology and Cellular Biophysics, Columbia University, 630 W 168th St, New York, NY 10032. E-mail jh577{at}columbia.edu
| Abstract |
|---|
|
|
|---|
Key Words: reactive oxygen species macrophages oxidized LDL CD11b/CD18 scavenger receptors
| Introduction |
|---|
|
|
|---|
Like macrophages, endothelial cells (ECs) and smooth muscle cells (SMCs) express scavenger-type receptors that interact with ligands expressed on oxLDL and on matrix proteins modified by oxidized lipids.1 These interactions stimulate macrophages, vascular SMCs, and vascular ECs to produce reactive oxygen species (ROS),1 eg, superoxide, which spontaneously reacts with water to generate other ROS, eg, H2O2. These ROS cause further oxidative modification of lipids and lipoproteins. Macrophages are thought to play the most prominent role in these processes owing to their high levels of ROS-generating enzymes, eg, NADPH oxidase and 5/12-lipoxygenase.1 We have reported that although SR-A plays a major role in promoting adhesion of human macrophages to oxLDL-containing matrixes, it appears to play little or no role in signaling ROS production.2 In contrast, antibodies that block interactions of the class B scavenger receptor CD36 with oxLDL have no effect on macrophage adhesion to oxLDL-containing matrixes but do inhibit ROS production by human macrophages adherent to these matrixes by
60%.2 To further explore these findings, we compared adhesion to and ROS production by resident peritoneal macrophages from mice genetically deficient in SR-A (SR-A-/-), CD36 (CD36-/-), or CD18 (CD18-/-) plated on oxLDL-containing matrixes with that of macrophages from background-appropriate wild-type mice plated on this matrix.
| Methods |
|---|
|
|
|---|
Mice
All mice used in these experiments were 6 to 8 weeks of age. SR-A-/-,3 CD36-/-,4 and CD18-/-5 mice are described elsewhere.
Cells
Mouse mononuclear cells were obtained by lavage of the peritoneal cavity and used in experiments immediately thereafter.6 Twenty-nine percent (±3%) of the cells harvested from the peritoneum of knockout mice and background-appropriate wild-type mice were macrophages, as indicated by their expression of nonspecific esterase and endocytosis of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-labeled acetylated LDL (not shown).7 Human monocytes were isolated from fresh buffy coats (New York Blood Center, New York, NY) and cultured for 3 to 5 days as described before being used in experiments.2
Adhesion
To compare adhesion of wild-type, SR-A-/-, CD36-/-, and CD18-/- mouse peritoneal mononuclear cells, we used surfaces coated with collagen IV alone (CIV), collagen IV and native LDL (CIV/LDL), or collagen IV and oxLDL (CIV/oxLDL). Because macrophages do not adhere efficiently to collagen IV,7 surfaces coated with this protein facilitate detection of adhesion-promoting ligands, such as oxLDL, absorbed to it.
To measure adhesion, 6-mm-diameter spots of multispot slides were incubated with 30 µL per spot of 50 µg/mL collagen IV (Fluka) in double-distilled water for 1 hour at 37°C, washed once with double-distilled water, air-dried, coated with 10 µg LDL per spot (Intracell) or oxLDL as described,2 air-dried again, and overlaid with 50 µL Krebs-Ringer buffer containing 1 mmol/L glucose (Sigma) and 0.1% bovine serum albumin (Sigma) (KRBGA solution) containing 2.5x104 mouse peritoneal mononuclear cells or human macrophages for 45 minutes at 37°C in a 5% CO2/95% air atmosphere. Slides were washed with KRBGA, and the number of adherent cells was determined by using CyQuant GR cell proliferation assay (Molecular Probes) according to the manufacturers instructions.
ROS Production
Accumulation of H2O2 as a representative ROS in the supernatant was measured with the Amplex RedTM H2O2 assay (Molecular Probes) according to the manufacturers instructions. The wells of 96-well, flat-bottomed microtiter plates were coated with CIV, CIV/LDL, or CIV/oxLDL as described above and overlaid with 150 µL KRBGA containing 20 µmmol/L Amplex RedTM (Molecular Probes), 0.2 U/mL horseradish peroxidase (Molecular Probes), and 3x105 mouse peritoneal mononuclear cells or human macrophages for 2 hours at 37°C in a 5% CO2/95% air atmosphere. Fluorescence of the product formed by the reaction between Amplex RedTM and H2O2 was assayed with a fluorescent plate reader.
Antibodies
Mouse peritoneal mononuclear cells or human macrophages were preincubated with KRBGA containing monoclonal rat anti-mouse CD18 IgG1;k (Pharmingen) or control rat IgG1;k (Pharmingen) at 0.4, 2, or 10 µg/mL; monoclonal mouse anti-human CD18 IgG1b (Ancell Corp) or control mouse IgG1b (AnCell) at 0.4, 2, or 10 µg/mL; or monoclonal rat anti-mouse/human CD11b IgG2b (Serotec) or control rat IgG2b (Pharmingen) at 0.04, 0.2, or 1 µg/mL for 15 minutes at 37°C in a 5% CO2/95% air atmosphere where indicated.
Statistical Analysis
All experiments were performed with triplicate samples for 3 lots of macrophages. Students t test was used to pairwise compare adhesion (Figures 1 and 3b) and accumulation of H2O2 (Figures 2 and 3a) by wild-type mouse macrophages plated on CIV/oxLDL with wild-type macrophages plated on CIV or CIV/LDL, or by knockout macrophages (SR-A-/-, CD36-/-, or CD18-/-) plated on CIV/oxLDL. Students t test was used to compare adhesion (not shown) and accumulation of H2O2 (Figure 3c) by human or wild-type mouse macrophages plated on CIV/oxLDL in the absence of antibody or EDTA (leftmost cluster of bars) with macrophages preincubated with anti-CD11b, anti-CD18, control antibodies (not shown), or EDTA. Data are presented as mean±SEM, with ** indicating P
0.01.
|
|
|
| Results |
|---|
|
|
|---|
13% of macrophages) from wild-type mice, SR-A-/- mice, and CD36-/- mice adhered to surfaces coated with CIV or CIV/LDL (Figure 1), whereas
23% of total mononuclear cells (
78% of macrophages) from wild-type, SR-A-/-, and CD36-/- mice adhered to surfaces coated with CIV/oxLDL (Figure 1). These findings indicate that neither SR-A nor CD36 is required for adhesion of murine peritoneal macrophages to oxLDL-containing matrixes and that other adhesion-mediating receptors, eg SR-BI,7 may mediate macrophage binding to ligands provided by oxLDL.
To assess whether adhesion to CIV, CIV/LDL, or CIV/oxLDL stimulates ROS production by SR-A-/-, CD36-/-, or wild-type murine macrophages, we incubated these cells on matrixes containing these proteins and assayed for accumulation of H2O2 in the supernatant as a representative ROS. Consistent with the findings of Maxeiner et al,2 wild-type mouse peritoneal macrophages produced very little ROS on surfaces coated with CIV or CIV/LDL (
33 pmol H2O2 per 3x105 cells/2 hours; Figure 2) but produced significantly more ROS on surfaces coated with CIV/oxLDL (
185 pmol H2O2 per 3x105 cells/2 hours; Figure 2). However, in contrast to the results predicted by Maxeiner et al,2 macrophages from SR-A-/- and CD36-/- mice produced at least as much ROS as did wild-type macrophages (
247±36 and
188±47 pmol H2O2 per 3x105 cells/2 hours, respectively; Figure 2). These findings show that receptors other than SR-A and CD36 can mediate adhesion of resident macrophages to oxLDL-containing matrixes and ROS production by these cells when they adhere to such matrixes.
Interestingly, neutrophils also have been shown to produce ROS on interaction with oxLDL (see Maeba et al8 and J.H., unpublished observations, 2000). Neutrophils are not found in atherosclerotic lesions and do not express detectable levels of SR-A or CD36 (Naito et al9 and J.H., unpublished observations, 2000) but do express high levels of the ß2-integrin CD11b/CD18 (also known as Mac-1, complement receptor 3, CR3). Neutrophils and macrophages can be induced to produce ROS when they adhere to surfaces containing ligands for CD11b/CD18 (eg, fibrinogen, iC3b10). This suggested a role for CD11b/CD18 in ROS production by macrophages. As anticipated, resident peritoneal macrophages from mice genetically deficient in the ß2-chain of CD11b/CD18 (CD18-/- mice) adhered as efficiently to matrixes containing CIV/oxLDL as did wild-type murine macrophages (Figure 3b). However, macrophages from CD18-/- mice produced
20% as much ROS as did wild-type macrophages on adhesion to this matrix (Figure 3a). The amount of ROS produced by CD18-/- macrophages adherent to CIV/oxLDL (
39 pmol H2O2 per 3x105 cells/2 hours; Figure 3a) was not significantly different from the amount secreted by wild-type macrophages adherent to surfaces containing CIV or CIV/LDL (
33 pmol H2O2 per 3x105 cells/2 hours; Figure 1). These results indicate that CD18 plays a hitherto-unanticipated role in oxLDL-stimulated ROS production by macrophages.
To further explore this finding, we assessed the effect of antibodies against mouse and human CD18 or CD11b on ROS production by mouse and human macrophages adherent to surfaces containing CIV/oxLDL. These antibodies almost completely inhibited ROS production by mouse or human macrophages. Neither anti-CD18 nor anti-CD11b IgG had any effect on adhesion of these cells to surfaces containing CIV/oxLDL (not shown). The same concentration of isotype-matched control IgG had no effect on mouse or human macrophage adhesion to or ROS production on CIV/oxLDL (not shown).
ß2-Integrins require divalent cations to bind ligands. To determine whether the divalent cationdependent, ligand-binding domain of CD11b/CD18 is involved in this system, we tested the effect of 5 mmol/L EDTA on adhesion and ROS production by mouse and human macrophages plated on CIV/oxLDL. EDTA had no effect on macrophage adhesion but caused an
80% decrease in ROS production by wild-type mouse and human macrophages plated on CIV/oxLDL (Figure 3c). To confirm that EDTA did not block ROS production per se, we tested ROS production by resident mouse peritoneal macrophages and by human blood monocyte-derived macrophages stimulated with 100 ng/mL phorbol myristate acetate or 10 mg/mL zymosan. The presence of EDTA had no effect on ROS production induced by these stimuli (data not shown).
Thus, by genetically eliminating expression of CD18, use of antibodies that masked the ligand-binding domain(s) of CD18, and chelation of divalent cations required for CD11/CD18 functions, we have disrupted a required step in ROS production by macrophages adherent to oxLDL-containing matrixes. Because antibodies against CD11b/CD18 are as effective in inhibiting ROS production as is the absence of all 4 ß2-integrins in CD18-/- macrophages, it appears that CD11b/CD18 is the ß2-integrin involved in this signaling pathway.
| Discussion |
|---|
|
|
|---|
Monocytes that enter the subendothelial space mature into macrophages that interact with and ingest oxLDL via scavenger receptors (eg, SR-A, SR-BI, CD36), thereby becoming foam cells.1 Interactions with matrix-bound oxLDL may also stimulate these macrophages to produce ROS in vivo, as they do in vitro (eg, Figures 1 through 3 and References 2 and 14). The NADPH oxidase and the 12/15-lipoxygenase pathways are thought to play important roles in the atherogenic effects of macrophages. NADPH oxidase is upregulated in macrophages in atherosclerotic lesions.15 Inhibitors of NADPH oxidase slow the appearance of vascular lesions in a rabbit model of atherosclerosis.16 In mouse models, however, genetic disruption of 2 subunits of NADPH oxidase (gp91phox17 and p47phox18) had no significant effect on lesion development. There are no reports of atherosclerosis in patients whose monocytes are deficient in NADPH oxidase (eg, chronic granulomatous disease). Macrophages from such patients retain the ability to produce ROS through the 15-lipoxygenase pathway,19,20 especially after treatment with cytokines21 (eg,
-interferon22). Furthermore, chronic granulomatous disease macrophages oxidize LDL in vitro, though with reduced efficiency.14
15-Lipoxygenase colocalizes with epitopes of oxLDL in human and rabbit atherosclerotic lesions.23 Genetic disruption of 12/15-lipoxygenases in a mouse model of atherosclerosis24 or inhibition of 15-lipoxygenase in a rabbit model25 of atherosclerosis has been reported to limit the progression of atherosclerotic lesions. These results suggest that macrophage production of ROS via both the NADPH and lipoxygenase pathways contributes to the development of atherosclerosis. The finding that the absence or inhibition of CD11b/CD18 reduces ROS production by macrophages adherent to a matrix containing oxLDL by
80% suggests that CD11b/CD18 plays a role in atherosclerosis. Nageh et al11 observed an
50% reduction in fatty streaks in mice whose CD18 genes had been knocked out.
Anti-CD18 antibodies reduce migration of monocytes across unstimulated human umbilical vein EC monolayers by
75%.26 However, when human umbilical vein EC monolayers are pretreated with proinflammatory substances (eg, lipopolysaccharide, tumor necrosis factor-
, or interleukin-1ß), migration is no longer inhibited by anti-CD18 antibodies but is blocked by antibodies against VLA-4 and VCAM-1.26 This suggests that monocyte migration across "inflamed" endothelium is CD18 independent. The findings reported here raise the possibility that the reduction in atherosclerotic lesion size observed by Nageh et al11 may reflect decreased production of ROS and other proinflammatory substances within the subendothelial compartment rather than reduced monocyte migration across the vascular endothelium into this compartment.
The mechanism by which CD11b/CD18 participates in ROS production by neutrophils and macrophages remains unresolved. At present, there is no evidence that CD11b/CD18 interacts directly with oxLDL. As documented here, ß2-integrins are not required for adhesion to oxLDL-containing matrixes (Figure 3b). It is possible that activation of CD11b/CD18 by signals generated by the interactions of specific cell surface receptors with matrix-bound oxLDL capacitates this receptor to organize/assemble the NADPH oxidase. Whatever mechanism is responsible, the findings reported here indicate a central and hitherto-unsuspected role for CD18 in regulating oxidant production by macrophages in atherosclerotic lesions.
In conclusion, CD11b/CD18 may be a significant player in regulating macrophage signaling pathways involved in atherogenesis. In humans, CD11b/CD18 may cooperate with CD36 in signaling ROS production on macrophage interaction with oxLDL.2 In macrophages from CD36-/- mice, however, CD36 is not required for this response (Figure 2). ROS and possibly other proinflammatory substances (eg, nitric oxide) produced by macrophages interacting with oxLDL may contribute to the initiation and/or progression of vascular disease by oxidizing extracellular matrix proteins, lipoproteins, and lipids and stimulating cell death. Inhibition of ROS or nitric oxide production27 has been demonstrated to slow progression of atherosclerosis. The findings reported here raise the possibility that agents that disrupt the participation of CD11b/CD18 in intracellular signaling pathways could slow the onset and/or progression of atherosclerosis and other diseases involving macrophage ROS production.
| Acknowledgments |
|---|
Received May 2, 2001; accepted June 14, 2001.
| References |
|---|
|
|
|---|
2.
Maxeiner H, Husemann J, Thomas CA, Loike JD, El Khoury J, Silverstein SC. Complementary roles for scavenger receptor A and CD36 of human monocyte-derived macrophages in adhesion to surfaces coated with oxidized low-density lipoproteins and in secretion of H2O2. J Exp Med. 1998; 188: 22572265.
3. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Kodama T, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997; 386: 292296.[Medline] [Order article via Infotrieve]
4. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice [see comments]. J Clin Invest. 2000; 105: 10491056.[Medline] [Order article via Infotrieve]
5.
Scharffetter-Kochanek K, Lu H, Norman K, van Nood N, Munoz F, Grabbe S, McArthur M, Lorenzo I, Kaplan S, Ley K, Smith CW, Montgomery CA, Rich S, Beaudet AL. Spontaneous skin ulceration and defective T cell function in CD18 null mice. J Exp Med. 1998; 188: 119131.
6.
Thomas CA, Li Y, Kodama T, Suzuki H, Silverstein SC, El Khoury J. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med. 2000; 191: 147156.
7. Husemann J, Loike J, Kodama T, Silverstein SC. Scavenger receptor class B type l (SR-BI) mediates adhesion of neonatal murine microglia to fibrillar ß-amyloid. J Neuroimmunol. 2001; 114: 142150.[Medline] [Order article via Infotrieve]
8. Maeba R, Maruyama A, Tarutani O, Ueta N, Shimasaki H. Oxidized low-density lipoprotein induces the production of superoxide by neutrophils. FEBS Lett. 1995; 377: 309312.[Medline] [Order article via Infotrieve]
9. Naito M, Kodama T, Matsumoto A, Doi T, Takahashi K. Tissue distribution, intracellular localization, and in vitro expression of bovine macrophage scavenger receptors. Am J Pathol. 1991; 139: 14111423.[Abstract]
10. Hoogerwerf M, Weening RS, Hack CE, Roos D. Complement fragments C3b and iC3b coupled to latex induce a respiratory burst in human neutrophils. Mol Immunol. 1990; 27: 159167.[Medline] [Order article via Infotrieve]
11.
Nageh MF, Sandberg ET, Marotti KR, Lin AH, Melchior EP, Bullard DC, Beaudet AL. Deficiency of inflammatory cell adhesion molecules protects against atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1997; 17: 15171520.
12. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275281.[Medline] [Order article via Infotrieve]
13. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894897.[Medline] [Order article via Infotrieve]
14. Aviram M, Fuhrman B. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of pro-oxidants vs. antioxidants. Mol Cell Biochem. 1998; 188: 149159.[Medline] [Order article via Infotrieve]
15.
Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation. 1999; 100: 14941498.
16. Holland JA, Johnson DK. Prevention of atherosclerosis using NADPH oxidase inhibitors. US Patent 5,902,831. 1999.
17.
Kirk EA, Dinauer MC, Rosen H, Chait A, Heinecke JW, LeBoeuf RC. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000; 20; 15291535.
18.
Hsich E, Segal BH, Pagano PJ, Rey FE, Paigen B, Deleonardis J, Hoyt RF, Holland SM, Finkel T. Vascular effects following homozygous disruption of p47(phox): an essential component of NADPH oxidase. Circulation. 2000; 101: 12341236.
19. Smith RL, Weidemann MJ. Reactive oxygen production associated with arachidonic acid metabolism by peritoneal macrophages. Biochem Biophys Res Commun. 1980; 97: 973980.[Medline] [Order article via Infotrieve]
20. Lim LK, Hunt NH, Weidemann MJ. Reactive oxygen production, arachidonate metabolism and cyclic AMP in macrophages. Biochem Biophys Res Commun. 1983; 114: 549555.[Medline] [Order article via Infotrieve]
21.
Jendrossek V, Peters AM, Buth S, Liese J, Wintergerst U, Belohradsky BH, Gahr M. Improvement of superoxide production in monocytes from patients with chronic granulomatous disease by recombinant cytokines. Blood. 1993; 81: 21312136.
22.
Gallin JI. Interferon-
in the treatment of the chronic granulomatous diseases of childhood. Clin Immunol Immunopathol. 1991; 61: S100S105.[Medline]
[Order article via Infotrieve]
23.
Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A. 1990; 87: 69596963.
24. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999; 103: 15971604.[Medline] [Order article via Infotrieve]
25. Bocan TM, Rosebury WS, Mueller SB, Kuchera S, Welch K, Daugherty A, Cornicelli JA. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis. 1998; 136: 203216.[Medline] [Order article via Infotrieve]
26. Chuluyan HE, Issekutz AC. VLA-4 integrin can mediate CD11/CD18-independent transendothelial migration of human monocytes. J Clin Invest. 1993; 92: 27682777.
27.
Detmers PA, Hernandez M, Mudgett J, Hassing H, Burton C, Mundt S, Chun S, Fletcher D, Card DJ, Lisnock J, Weikel R, Bergstrom JD, Shevell DE, Hermanowski-Vosatka A, Sparrow CP, Chao YS, Rader DJ, Wright SD, Pure E. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol. 2000; 165: 34303435.
This article has been cited by other articles:
![]() |
J. C. Todt, B. Hu, and J. L. Curtis The scavenger receptor SR-A I/II (CD204) signals via the receptor tyrosine kinase Mertk during apoptotic cell uptake by murine macrophages J. Leukoc. Biol., August 1, 2008; 84(2): 510 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Pluskota, O. I. Stenina, I. Krukovets, D. Szpak, E. J. Topol, and E. F. Plow Mechanism and effect of thrombospondin-4 polymorphisms on neutrophil function Blood, December 1, 2005; 106(12): 3970 - 3978. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sethy-Coraci, L. W. Crock, and S. C. Silverstein PAF-receptor antagonists, lovastatin, and the PTK inhibitor genistein inhibit H2O2 secretion by macrophages cultured on oxidized-LDL matrices J. Leukoc. Biol., November 1, 2005; 78(5): 1166 - 1174. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Jozefowski and L. Kobzik Scavenger receptor A mediates H2O2 production and suppression of IL-12 release in murine macrophages J. Leukoc. Biol., November 1, 2004; 76(5): 1066 - 1074. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.D. Loike, D.Y. Shabtai, R. Neuhut, S. Malitzky, E. Lu, J. Husemann, I.J. Goldberg, and S.C. Silverstein Statin Inhibition of Fc Receptor-Mediated Phagocytosis by Macrophages Is Modulated by Cell Activation and Cholesterol Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 2051 - 2056. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kusmartsev, Y. Nefedova, D. Yoder, and D. I. Gabrilovich Antigen-Specific Inhibition of CD8+ T Cell Response by Immature Myeloid Cells in Cancer Is Mediated by Reactive Oxygen Species J. Immunol., January 15, 2004; 172(2): 989 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Akiba, Y. Yoneda, S. Ohno, M. Nemoto, and T. Sato Oxidized LDL activates phospholipase A2 to supply fatty acids required for cholesterol esterification J. Lipid Res., September 1, 2003; 44(9): 1676 - 1685. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |